Work

Overall survival (OS) and biomarker results from combat: A phase 2 study of bipolar androgen therapy (BAT) plus nivolumab for patients with metastatic castrate-resistant prostate cancer (mCRPC).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.5064

Authors: Mark Christopher Markowski, Mary-Ellen Taplin, Rahul Raj Aggarwal, Laura Sena, Hao Wang, Aliya Lalji, Jennifer Meyers, Alyza Skaist, Anuj Gupta, Carolina Gomes-Alexandre, Tracy Jones, Jessica Hicks, Sushant Kachhap, Srinivasan Yegnasubramanian, Angelo M De Marzo, Samuel R. Denmeade, Emmanuel S. Antonarakis

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Dana-Farber Cancer Institute, UCSF Helen Diller Family Comprehensive Cancer Center, Johns Hopkins Medicine, Masonic Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4286295043

Cites:

Cited by: 4

Related to: 10